Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 1, 1999, Pages 188-193

  Eliot, Lise A ^a   Jamali, Fakhreddin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; NIFEDIPINE;

ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG POTENTIATION; HYPERLIPIDEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEPTANOIC ACIDS; HYPERLIPIDEMIAS; MALE; NIFEDIPINE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032864348     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Achike FI and Dai S (1990) Cardiovascular responses to verapamil and nifedipine in hypoventilated and hyperventilated rats. Br J Pharmacol 100:102-106.
2. Akhlaghi F, McLacklan AJ, Keogh AM and Brown KF (1997) Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 44:537-542.
3. Brajtburg J, Elberg S, Bolard J, Kobayaski GS, Levy RA, Ostlund RE, Schlessinger D and Medoff, G (1984) Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis 149:986-997.
4. Brunner LJ, Vadiei K and Luke DR (1988) Cyclosporine disposition in the hyperlipidemic rat model. Res Commun Chem Pathol Pharmacol 59:339-348.
5. Catapano, AL (1997) Calcium antagonists and atherosclerosis. Experimental evidence. Eur Heart J 18 (Suppl A):A80-A86.
6. Danon A and Chen Z (1998) Binding of imipramine to plasma proteins: Effect of hyperlipoproteinemia. Clin Pharmacol Ther 25:316-321.
7. Donnelly R, Elliot HL and Meredith PA (1994) Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists. Clin Pharmacokinet 26:472-485.
8. Dokladalova J, Tykal JA, Coco SJ, Durkee PE, Quercia GT and Korst JJ (1982) Occurrence and measurement of nifedipine and its nitropyridine derivatives in human blood plasma J Chromatogr 231:451-458.
9. Dutkiewicz G, Wojcicki J and Gawronska-Szklarz B (1994) Effect of hyperlipidemia on pharmacokinetics of free phenytoin. Neur Neurochir Pol 28:203-211.
10. Eliot L (1988) The calcium channel blocker controversy - A caution to physicians and pharmacists. J Pharm Pharma Sci (www.ualberta.ca/~csps) 1:13-14.
11. Eliot LA, Foster RT and Jamali F (1999) Effects of hyperlipidemia on the pharmacokinetics of nifedipine. Pharmacol Res 16:309-313.
12. Ferrari, R (1997) Major differences among the three classes of calcium antagonists. Eur Heart J 18 (Suppl A):A56-A70.
13. Fielding PE. and Fielding CJ (1996) Dynamics of lipoprotein transport in the human circulatory system, in Biochemistry of Lipids, Lipoproteins, and Membranes (Vance DE and Vance JE eds), pp 495-541, Elsevier Publishing Co., Amsterdam.
14. Furberg CD, Psaty BM and Meyer JV (1995) Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92:1326-1331.
15. Grundy JS, Kherani R and Foster RT (1994) Sensitive high-performance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection. J Chromatogr Biomed Appl 654:146-151.
16. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
17. Gurusinghe A, De Niese M, Renaud JF and Austin L (1988) The binding of lipoproteins to human muscle cells: binding and uptake of LDL, HDL, and alpha-tocopherol. Muscle Nerve 11:1231-1239.
18. Holford NHG and Sheiner LB (1981) Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:429-453.
19. Irizar A, Barnett CR, Flatt PR and Ioannides C (1995) Defective expression of cytochrome P450 proteins in the liver of the genetically obese Zucker rat. Eur J Pharmacol 293:385-393.
20. Kacmarek RM, Mac CW and Dimas S (1985) Hemodynamic monitoring, in The Essentials of Respiratory Therapy (Kacmarek RM, Mac CW and Dimas S eds), Medical Book Inc., Chicago.
21. Liao W, Angelin B and Rudling M (1997) Lipoprotein metabolism in the fat Zucker rat: Reduced basal expression but normal regulation of hepatic low density lipoprotein receptors. Endocrinology 138:3282.
22. Lindholm A and Henricsson S (1989) Intra- and interindividual variability in the free fraction of cyclosporine in plasma recipients of renal transplants. Ther Drug Monit 11:623-630.
23. Lithell H, Odlind B, Selinus I, Lindberg A, Lindstrom B and Frodin L (1986) Is the plasma lipoprotein pattern of importance for treatment with cyclosporine? Transplant Proc 18:50-51.
24. Martin RJ, Wangsness PJ and Gahagan, JH (1978) Diurnal changes in serum metabolites and hormones in lean and obese Zucker rats. Horm Metab Res 10: 187-192.
25. Oravcova J, Sojkova D, Fetkovska N and Tmovec T (1994) Factors influencing isradipine and amlodipine binding to human plasma lipoproteins. Blood Press 1:61-64.
26. Raasch RH (1988) Hyperlipidemias, in Applied Therapeutics. The Clinical Use of Drugs (Young LY and Koda-Kimble MA eds), pp 1743-1760, Edwards Brothers, Ann Arbor, MI.
27. Rosenkranz H, Schlossmann K and Scholtan W (1974) The binding of 4-(2′-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (nifedipine) as well as other coronary active substances to serum albumins. Arzneimittelforschung 24:455-466.
28. Russell J, Koeslag D, Amy R and Dolphin P (1989) Plasma lipid secretion and clearance in hyperlipidemic JCR-LA-corpulent rats. Arteriosclerosis 9:869-876.
29. Urien S, Albengres E, Comte A and Kiechel JROJP (1985) Plasma protein binding and erythrocyte partitioning of nicardipine in vitro. J Cardiovasc Pharmacol 7:891-898.
30. Vadiei K, Lopez-Berestein and Luke DR (1990) Disposition, and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model. Int J Obesity 14:465-472.
31. Venitz J (1995) Pharmacokinetic-pharmacodynamic modeling of reversible drug effects, in Handbook of Pharmacokinetic-Pharmacodynamic Correlation (Derendorf H and Hochhaus G eds), pp 1-34, CRC, Boca Raton, FL.
32. Wasan KM and Conklin JS (1997) Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin Infect Dis 24:78-80.
33. Winocour PL (1996) Lipids and the hypertensive patient - should they really make a difference to management decisions?, in Lipids: Current Perspectives (Betteridge DJ ed), pp 115-134, Mosby, London.
34. Wout ZGM, Pec EA, Maggiore, JA, Williams RH, Palicharla P and Johnston TP (1992) Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J Par Sci Tech 46:192-200.